X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1335) 1335
oxazines - therapeutic use (1034) 1034
male (757) 757
female (626) 626
animals (616) 616
benzoxazines (613) 613
index medicus (489) 489
hiv infections - drug therapy (488) 488
pharmacology & pharmacy (475) 475
adult (452) 452
oxazines - pharmacology (406) 406
anti-hiv agents - therapeutic use (366) 366
middle aged (351) 351
reverse transcriptase inhibitors - therapeutic use (329) 329
drug therapy, combination (258) 258
oxazines - adverse effects (258) 258
oxazines (248) 248
oxazines - administration & dosage (245) 245
mice (230) 230
infectious diseases (219) 219
rats (217) 217
oxazines - chemistry (202) 202
oxazines - metabolism (196) 196
aged (187) 187
ofloxacin (183) 183
dose-response relationship, drug (173) 173
treatment outcome (158) 158
immunology (157) 157
viral load (151) 151
clinical trials as topic (140) 140
efavirenz (132) 132
oxazines - pharmacokinetics (132) 132
hiv protease inhibitors - therapeutic use (129) 129
analysis (127) 127
hiv infections - virology (122) 122
anti-hiv agents - adverse effects (118) 118
time factors (118) 118
cd4 lymphocyte count (115) 115
nevirapine - therapeutic use (114) 114
toxicology (111) 111
reverse transcriptase inhibitors - adverse effects (105) 105
virology (104) 104
hiv (101) 101
biochemistry & molecular biology (98) 98
drug therapy (95) 95
in-vitro (93) 93
pyridines - therapeutic use (92) 92
microbiology (91) 91
anti-infective agents - therapeutic use (90) 90
hiv-1 - drug effects (89) 89
kinetics (89) 89
methylcellulose - analogs & derivatives (89) 89
adolescent (88) 88
antiretroviral therapy, highly active (88) 88
lactose - analogs & derivatives (88) 88
dideoxynucleosides - therapeutic use (84) 84
chemistry, medicinal (83) 83
oxazines - blood (80) 80
cell survival - drug effects (78) 78
chemistry, multidisciplinary (78) 78
disease models, animal (77) 77
anti-hiv agents - administration & dosage (76) 76
adenine - analogs & derivatives (75) 75
lamivudine - therapeutic use (75) 75
microbial sensitivity tests (74) 74
structure-activity relationship (74) 74
xanthenes (73) 73
drug interactions (72) 72
neurosciences (72) 72
nevirapine (72) 72
research (72) 72
rna, viral - blood (71) 71
adenine - therapeutic use (70) 70
cell line, tumor (70) 70
drugs (70) 70
fluorescence (69) 69
pharmacokinetics (68) 68
hiv infection (67) 67
in vitro techniques (66) 66
reverse transcriptase inhibitors - administration & dosage (66) 66
double-blind method (65) 65
hiv-1 (65) 65
rats, sprague-dawley (64) 64
administration, oral (63) 63
oxazines - chemical synthesis (63) 63
protease inhibitors (62) 62
therapy (62) 62
drug evaluation (61) 61
anti-bacterial agents - therapeutic use (60) 60
drug administration schedule (60) 60
antiretroviral therapy (59) 59
antiviral agents (59) 59
drug combinations (59) 59
drug delivery systems (59) 59
health aspects (59) 59
article (58) 58
care and treatment (58) 58
hiv-1 - genetics (57) 57
physiological aspects (57) 57
cells, cultured (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1758) 1758
German (61) 61
Japanese (52) 52
French (39) 39
Italian (20) 20
Russian (14) 14
Spanish (9) 9
Chinese (8) 8
Dutch (4) 4
Polish (4) 4
Bulgarian (2) 2
Czech (2) 2
Turkish (2) 2
Croatian (1) 1
Danish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2006, Volume 354, Issue 3, pp. 251 - 260
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 09/2018, Volume 18, Issue 9, pp. 586 - 595
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 13, pp. 2578 - 2585
Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in... 
RHEUMATOID-ARTHRITIS | BCR | B-CELL LYMPHOMA | RESPONSE CRITERIA | R-CHOP | THERAPEUTIC TARGET | PHASE-III | TYROSINE KINASE INHIBITOR | FOLLICULAR LYMPHOMA | HEMATOLOGY | EXPRESSION | Humans | Middle Aged | Neoplasm Proteins - physiology | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Protein-Tyrosine Kinases - physiology | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Oxazines - administration & dosage | Syk Kinase | Lymphoma, Non-Hodgkin - drug therapy | Oxazines - pharmacology | Pyridines - therapeutic use | Hematologic Diseases - chemically induced | Pyridines - administration & dosage | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Treatment Outcome | Oxazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Intracellular Signaling Peptides and Proteins - physiology | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 01/2014, Volume 15, Issue 1, pp. 3 - 9
Chemokines produced in distinct tissue microenvironments sustain migration of mature lymphocytes in lymphoglandula. Chemokine receptors expressed on chronic... 
microenvironment | targeted therapy | chemokines | chronic leukemia lymphoma | chemokines receptors | Chemokines receptors | Microenvironment | Targeted therapy | Chronic leukemia lymphoma | Chemokines | B-CELL RECEPTOR | SURVIVAL | ACTIVATION | PCI-32765 | PHASE-II | CXCR4 | IN-VITRO | ONCOLOGY | TYROSINE KINASE INHIBITOR | NODE MICROENVIRONMENT | GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Heterocyclic Compounds - pharmacology | Tumor Microenvironment | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Thiazoles - therapeutic use | Molecular Targeted Therapy | Thalidomide - analogs & derivatives | Antineoplastic Agents - pharmacology | Purines - therapeutic use | Quinazolinones - pharmacology | Oxazines - pharmacology | Pyridines - therapeutic use | Dasatinib | Purines - pharmacology | Receptors, CXCR4 - antagonists & inhibitors | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Clinical Trials as Topic | Pyrimidines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Receptors, CXCR4 - metabolism | Chemokine CXCL12 - metabolism | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Thiazoles - pharmacology | Heterocyclic Compounds - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Niacinamide - pharmacology | Quinazolinones - therapeutic use | Thalidomide - therapeutic use | Review
Journal Article
Cancer Research, ISSN 0008-5472, 07/2009, Volume 69, Issue 13, pp. 5424 - 5432
Journal Article
Journal Article